The SEC says Jessica Richman and Zachary Apte misrepresented that their biotech startup was generating reliable revenue from insurance reimbursements.
The $425 million deal gives Merck access to a promising therapy for treating seriously ill COVID-19 patients.
The biotech is preparing for the global launch of its potential COVID-19 vaccine.
The pharma giant could pay as much as $4 billion if performance targets are met.
The SEC says Arrayit President Mark Schena falsely claimed the company had developed a test and it was awaiting emergency FDA approval.
The deal will move Illumina “deeper into the application of its gene-sequencing technology to the diagnosis and treatment of patients."
The SEC says the biotech firm made improper payments to Turkish and Russian officials to secure favorable treatment for its main drug.
Interim data from a Phase 1 study showed Moderna's vaccine candidate stimulated an immune response against the virus in people.
The commission has halted trading in the shares of three companies that have said they are developing a drug candidate for treating COVID-19.
The grant from the U.S. government will boost Moderna's efforts to develop what is “among the most advanced coronavirus vaccine candidates.”
Here's how to shift the decision-making process from a misunderstood art toward a mainstream science.
The C-suite executives allegedly improperly recognized revenue from distributors with which MiMedx had secret side arrangements.
